About Us
Equillium is a clinical-stage biopharmaceutical company developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Our lead asset, itolizumab, targets the CD6-ALCAM signaling pathway, which plays a central role in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab has potential to be a best-in-class disease-modifying therapeutic and is currently being evaluated in clinical trials in multiple indications, including acute graft-versus-host disease, uncontrolled asthma, and SLE / lupus nephritis.